| Similar Articles |
|---|
 |
Managed Care
March 2005
Thomas Morrow |
Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration.   |
Chemistry World
May 9, 2011
Andrew Turley |
New data reignites eye drug debate Interim results from a much anticipated comparative study of two drugs support what many ophthalmologists already believe: that ranibizumab and bevacizumab are equally good for the treatment of neovascular age related macular degeneration. |
The Motley Fool
November 19, 2011
Luke Timmerman |
Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
The Motley Fool
May 24, 2005
Charly Travers |
Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note. |
The Motley Fool
October 2, 2007
Brian Orelli |
Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data. |
Chemistry World
May 21, 2014
Phillip Broadwith |
Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
BusinessWeek
August 16, 2004
Arlene Weintraub |
The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near. |
Chemistry World
September 24, 2014
Phillip Broadwith |
Review says cheaper drug is safe for eye disease Researchers have added weight to the argument that health services should use the cancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration, instead of the more expensive Lucentis (ranibizumab). |
Managed Care
January 2004
Thomas Morrow |
Choking Off a Tumor's Blood Supply Angiogenesis blockade is a 30-year-old concept, but it will soon make the leap from lab bench to pharmacy shelf. |
BusinessWeek
February 21, 2005
Gene G. Marcial |
Iridex May Open More Investors' Eyes Iridex's stock price has fluctuated since initial results of clinical trials on its transpupillary thermotherapy product for age-related [wet] macular degeneration, a leading cause of blindness. |
The Motley Fool
August 21, 2008
Brian Lawler |
Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment. |
Chemistry World
April 2, 2015
Emma Stoye |
Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration. |
AskMen.com
Joshua Levine |
Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
March 2010
Peg Gray-Vickrey |
Gathering pearls of knowledge for assessing older adults If you attended nursing school more than 10 years ago, you may have received limited education about gerontological nursing. But as baby boomers age, this is becoming an increasingly important area of nursing practice. |
Chemistry World
January 13, 2011
Andrew Turley |
UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
The Motley Fool
July 5, 2006
Brian Lawler |
Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Chemistry World
June 3, 2014
Phillip Broadwith |
Drug companies rapped for anticompetitive behavior The Italian health ministry is following up on rulings from the country's competition authorities and demanding billions of euros in damages resulting from anticompetitive behavior. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
The Motley Fool
January 5, 2005
Rich Duprey |
Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years. |
Pharmaceutical Executive
August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
The Motley Fool
October 29, 2007
Brian Lawler |
QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs. |
The Motley Fool
August 31, 2004
Charly Travers |
Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one. |
Food Processing
October 2008 |
New Clues on Cause of AMD Researchers have discovered that a diet rich in antioxidants seems to hold Age-related macular degeneration at bay. |
Chemistry World
April 2012
Anthony King |
Making Light Work Could light prove to be the ultimate weapon in the battle against deadly superbugs? |
The Motley Fool
January 21, 2005
Charly Travers |
Seeing the Value in QLT A narrow-minded market could be creating a great drug value. |
Chemistry World
June 21, 2006
Katharine Sanderson |
Peptide Agent Tracks Angiogenesis A molecular imaging agent that can track the progress of tumour growth is about to be trialled by GE Healthcare. |
Chemistry World
May 30, 2008
Michael Gross |
Improving photodynamic cancer therapy Chemists in the UK and Canada have developed a new molecule that can help doctors to destroy cancer cells with unprecedented precision, using a technique known as photodynamic therapy (PDT). |
AskMen.com
Alex Santoso |
5 Tips For Good Vision Health Because in the United States there are 300,000 men who are blind and 1.1 million men with impaired vision, here's a review of five things you can do for good vision health. |
InternetNews
May 12, 2010 |
AMD Expands Vision Product Offerings The successful branding program for all-AMD laptops grows on the notebook side and expands into desktops. |
InternetNews
January 4, 2010 |
AMD's 'Vision' Now Includes Business Branding Chipmaker AMD is emphasizing value over technobabble in marketing to SMBs. |
